<DOC>
	<DOCNO>NCT02840409</DOCNO>
	<brief_summary>This open-label , randomize , multi-center , comparator Phase II trial look addition Bevacizumab Vinblastine chemotherapy naïve pediatric patient progressive Low Grade Glioma age 6 month less than18 year age time initiation therapy . Participants randomize Arm A Arm B . Arm A include 68 week single agent Vinblastine administer weekly IV . Arm B include 68 week Vinblastine administer weekly IV addition 12 dos Bevacizumab administer every two week IV initial 24 week . Randomization take place time registration take account NF1 BRAF-KIAA1549-fusion status .</brief_summary>
	<brief_title>Vinblastine +/- Bevacizumab Children With Unresectable Progressive Low Grade Glioma ( LGG )</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>1 . Children adolescent age 6 month &lt; 18 year old Low Grade Glioma ( See Appendix I ) . 2 . All patient must submit tumour tissue ( fresh tumour tissue recommend ) pathological confirmation LGG central lab . Exceptions make patient neurofibromatosis type 1 previously biopsy . NF1 patient eligible without tissue confirmation must definitive clinical radiographic evidence tumour progression risk significant neurologic deterioration require immediate therapy . If tissue sample NF1 patient available previous biopsy , require submitted Central Review Hospital Sick Children . 3 . Patients must progressive disease follow surgical excision base clear radiological clinical evidence progression , incomplete excision ( &lt; 95 % &gt; 1.0 cm2 residual tumour ) necessity begin treatment risk neurological impairment progression . 4 . All patient study must measurable tumour ( &gt; 1.0 cm2 residual tissue resection perform ) within 28 day registration . 5 . Patients must receive prior therapy include chemotherapy , biological modifier and/or radiation treatment tumour exception surgery . 6 . Patient able start treatment within 14 work day randomization . 7 . Post pubertal teenager sexually active agree use one effective method contraception treatment period least 6 month last dose study drug . 8 . Lansky performance status &gt; 50 % patient &lt; 16 year age . Karnofsky performance status &gt; 50 % patient ≥ 16 year age . 9 . Patients neurologic deficit must deficits stable minimum 1 week prior registration . 10 . Patients receive corticosteroid must stable decrease dose least 1 week prior registration . 11 . Life expectancy &gt; 2 month time registration . 12 . Parents/guardians must provide write informed consent agree ( patient ) comply study protocol . 13 . Written assent patient accord institutional guideline . 14 . Patients must adequate bone marrow function within 2 week prior registration : Hemoglobin ≥ 10 g/dL ( may support ) Neutrophil count ≥ 1.0 × 109/dL Platelet count ≥ 100 × 109/L ( transfusion independent ) 15 . Patients therapeutic dose anticoagulant must INR ≤ 1.5 aPTT ≤ 1.5x institutional ULN age . Anticoagulation permit prior randomization condition patient , accord local clinical practice guideline approve product labeling , adequately anticoagulated prior randomization . Patients take anticoagulant must INR aPTT within institutional normal range . 16 . Patients must satisfactory liver function within 2 week prior registration : AST ≤ 3x institutional ULN age ALT ≤ 3x institutional ULN age Total Bilirubin ≤ 1.5x institutional ULN age 17 . Patients must satisfactory renal function within 2 week prior registration : Serum creatinine must ≤ 1.5 x ULN age . If serum creatinine ≥ 1.5× ULN , glomerular filtration rate ( either estimate formal ) must &gt; 90 mL/min/1.73 m2 , patient enrol . Absence clinically significant proteinuria , define screen early morning urine ( urine protein &lt; 1g/L and/or albumin/creatinine ratio &lt; 1.0 ( mg/mmol ) ) . If urine protein ≥ 1g/L , Urine Protein Creatinine ( UPC ) ratio calculate . If UPC ratio &gt; 0.5 , 24hour urine protein obtain level &lt; 1000 mg/24 hour patient enrollment . Quality Life Correlative Study Inclusion Criteria ( Optional ) : 1 . Age ≥ 3 &lt; 18 year . 2 . English Spanishspeaking . 3 . No known history significant neurodevelopmental disorder prior diagnosis LGG ( e.g. , Down syndrome , Fragile X , William 's Syndrome , mental retardation ) . Patients NF1 exclude . 4 . No significant motor sensory impairment would prevent computer use perception visual auditory test stimulus . 1 . Children 6 month age . 2 . Pregnant lactating woman . 3 . Use investigational agent , systemic , targeted immunotherapy prior first dose study treatment . 4 . Any bleeding diathesis significant coagulopathy risk bleeding ( i.e . absence therapeutic anticoagulation ) . 5 . Patients evidence new symptomatic CNS hemorrhage ( &gt; grade I ) baseline MRI . 6 . Any significant cardiovascular disease , e.g . aortic aneurysm require surgical repair recent arterial thrombosis , CVAs , transient ischemic attack ( TIAs ) , systemic hypertension ( i.e. , systolic diastolic BP ≥ 95th percentile age , sex ) , prior history hypertensive crisis hypertensive encephalopathy stroke , uncontrolled cardiac arrhythmia within 6 month prior baseline visit . 7 . Any previous venous thromboembolism Grade 3 high ( NCI CTCAE v. 4.03 ) . 8 . History abdominal fistula , GI perforation , intraabdominal abscess active GI bleeding within 6 month prior first study treatment . 9 . Unresolved infection . 10 . An active peptic duodenal ulcer . 11 . Major surgical procedure ( see Table 2 ) , brain surgery , open biopsy significant traumatic injury within 28 day prior registration anticipation need major ( elective ) surgery course study treatment . 12 . Intermediate surgical procedure ( see Table 2 ) within 2 week registration . 13 . Minor surgical procedure ( see Table 2 ) within 3 day prior start treatment ( include placement central line , include PICC line ) . Insertion portacath require 7 day interval prior start treatment . 14 . Nonhealing surgical wound . 15 . A bone fracture satisfactorily heal . 16 . Concomitant use following : Aspirin ( &gt; 325mg/day ) within 10 day Baseline Visit Clopidogrel ( &gt; 75mg/day ) within 10 day Baseline Visit Use therapeutic oral parenteral anticoagulant thrombolytic agent therapeutic purpose INR aPTT outside therapeutic standard accord institutional guideline within 10 day first dose Bevacizumab . Note : The use fulldose oral parenteral anticoagulant permit long INR aPTT within therapeutic limit ( accord medical standard institution ) patient stable dose anticoagulant least two week time Baseline Visit . Prophylactic use anticoagulant allow .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>